Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Free Report

White Paper_2017_State of China Life Science

State of China Life Science - 2017H1

Over $10B invested in last 18 months! Download free report on life science investment in China.

Hua Medicine Begins Phase I Trial of Novel Diabetes Treatment

publication date: Sep 6, 2013
View a Printer Friendly version of this page, allowing you to print the page.
Hua Medicine has begun a China Phase I clinical trial of a novel Glucokinase activator treatment for diabetes 2. The CFDA gave HMS5552, as the Hua drug is known, the designation of type 1.1 novel drug because no drug of the Glucokinase activator class has been approved anywhere in the world. Hua in-licensed China rights to the drug from Roche two years ago. In a statement, Dr. Li Chen, CEO of Hua Medicine, noted that it was a significant milestone for Hua to start clinical development in China of an innovative diabetes treatment that is intended for the world’s market. More details....

Stock Symbol: (SX: ROG)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China